Terms: = Leukemia AND FGFR1OP, FOP, 11116, ENSG00000213066 AND Treatment
6 results:
1. Fear of progression in parents of childhood cancer survivors: prevalence and associated factors.
Peikert ML; Inhestern L; Krauth KA; Escherich G; Rutkowski S; Kandels D; Schiekiera LJ; Bergelt C
J Cancer Surviv; 2022 Aug; 16(4):823-833. PubMed ID: 34302272
[TBL] [Abstract] [Full Text] [Related]
2. Fear of progression in parents of childhood cancer survivors: A dyadic data analysis.
Peikert ML; Inhestern L; Krauth KA; Escherich G; Rutkowski S; Kandels D; Bergelt C
Psychooncology; 2020 Oct; 29(10):1678-1685. PubMed ID: 32779255
[TBL] [Abstract] [Full Text] [Related]
3. Early clinical observations on the use of imatinib mesylate in fop: A report of seven cases.
Kaplan FS; Andolina JR; Adamson PC; Teachey DT; Finklestein JZ; Ebb DH; Whitehead B; Jacobs B; Siegel DM; Keen R; Hsiao E; Pignolo RJ
Bone; 2018 Apr; 109():276-280. PubMed ID: 28736245
[TBL] [Abstract] [Full Text] [Related]
4. Fear of Progression in Outpatients With Chronic Myeloid leukemia on Oral Tyrosine Kinase Inhibitors.
Hefner J; Csef EJ; Kunzmann V
Oncol Nurs Forum; 2016 Mar; 43(2):190-7. PubMed ID: 26906130
[TBL] [Abstract] [Full Text] [Related]
5. Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer.
Mano Y; Takahashi K; Ishikawa N; Takano A; Yasui W; Inai K; Nishimura H; Tsuchiya E; Nakamura Y; Daigo Y
Cancer Sci; 2007 Dec; 98(12):1902-13. PubMed ID: 17888034
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation.
Zeiser R; Spyridonidis A; Wäsch R; Ihorst G; Grüllich C; Bertz H; Finke J
Leukemia; 2005 May; 19(5):814-21. PubMed ID: 15772700
[TBL] [Abstract] [Full Text] [Related]
